Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Jounce Therapeutics Inc (JNCE)

Jounce Therapeutics Inc (JNCE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 402,171
  • Shares Outstanding, K 51,232
  • Annual Sales, $ 62,340 K
  • Annual Income, $ -43,840 K
  • 60-Month Beta 1.11
  • Price/Sales 6.38
  • Price/Cash Flow N/A
  • Price/Book 1.21
Trade JNCE with:

Options Overview

Details
  • Implied Volatility 99.65%
  • Historical Volatility 65.58%
  • IV Percentile 17%
  • IV Rank 25.10%
  • IV High 206.13% on 12/07/20
  • IV Low 63.97% on 11/16/20
  • Put/Call Vol Ratio 0.00
  • Today's Volume 220
  • Volume Avg (30-Day) 100
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 769
  • Open Int (30-Day) 1,183

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.39
  • Number of Estimates 6
  • High Estimate -0.02
  • Low Estimate -0.59
  • Prior Year -0.73
  • Growth Rate Est. (year over year) +46.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.13 +53.02%
on 08/17/21
7.88 -0.38%
on 09/16/21
+2.64 (+50.67%)
since 08/16/21
3-Month
5.03 +56.06%
on 08/02/21
7.88 -0.38%
on 09/16/21
+0.47 (+6.37%)
since 06/16/21
52-Week
5.03 +56.06%
on 08/02/21
14.84 -47.10%
on 03/11/21
-1.57 (-16.62%)
since 09/16/20

Most Recent Stories

More News
Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors

Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of...

JNCE : 7.85 (+1.16%)
Jounce Therapeutics, Inc. (JNCE) Reports Q2 Loss, Tops Revenue Estimates

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 78.95% and 167.71%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?...

JNCE : 7.85 (+1.16%)
Jounce Therapeutics Reports Second Quarter 2021 Financial Results

- INNATE monotherapy dose escalation enrollment completed and target dose selected, on track to initiate indication specific expansions in third quarter 2021-

JNCE : 7.85 (+1.16%)
Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Conference Call on Thursday, August 5, 2021

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report...

JNCE : 7.85 (+1.16%)
Jounce Therapeutics to Participate in William Blair's Biotech Focus Conference

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Dmitri Wiederschain,...

JNCE : 7.85 (+1.16%)
Gilead (GILD) Gains 19% YTD: What to Expect in The Second Half?

Gilead (GILD) maintains momentum in the year so far on the back of Veklury for the treatment of COVID-19 and the same is expected to continue in the second half.

NVO : 102.38 (+1.10%)
MRK : 71.97 (-1.15%)
GILD : 71.33 (-0.60%)
JNCE : 7.85 (+1.16%)
Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, and Provides a Portfolio Update at 2021 R&D Day

- INNATE study rapidly advancing; updates to be provided on enrollment status and receptor occupancy; expansion cohorts expected to open for enrollment in third quarter of 2021-

JNCE : 7.85 (+1.16%)
Jounce Therapeutics to Host Virtual R&D Day on June 23, 2021

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it will host a virtual...

JNCE : 7.85 (+1.16%)
Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement with Gilead Sciences and FDA Clearance of Investigational New Drug Application for Anti-CCR8 Antibody

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the U.S. Food and...

JNCE : 7.85 (+1.16%)
GILD : 71.33 (-0.60%)
Jounce Therapeutics to Participate in Fireside Chat at the Raymond James Human Health Innovation Conference

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray,...

JNCE : 7.85 (+1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator,...

See More

Key Turning Points

3rd Resistance Point 8.90
2nd Resistance Point 8.39
1st Resistance Point 8.12
Last Price 7.85
1st Support Level 7.34
2nd Support Level 6.83
3rd Support Level 6.56

See More

52-Week High 14.84
Fibonacci 61.8% 11.09
Fibonacci 50% 9.94
Fibonacci 38.2% 8.78
Last Price 7.85
52-Week Low 5.03

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar